-
公开(公告)号：US07288534B2
公开(公告)日：2007-10-30
申请号：US10366704
申请日：2003-02-14
申请人： David Modrak , David M. Goldenberg
发明人： David Modrak , David M. Goldenberg
CPC分类号： A61K31/704 , A61K31/513 , A61K31/688 , A61K45/06 , A61K2300/00
摘要： Cytotoxic tumor therapy in a patient is enhanced by co-administration of sphingomyelin. The invention most likely enhances a tumor cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. A method of treating rheumatoid arthritis also is provided.
摘要翻译： 通过共同施用鞘磷脂增强患者的细胞毒性肿瘤治疗。 本发明最有可能增强肿瘤细胞通过增加所有细胞区室中鞘磷脂水平进行神经酰胺诱导的细胞凋亡的能力，从而为活化的鞘磷脂酶提供足够的底物。 还提供了治疗类风湿性关节炎的方法。
-
公开(公告)号：US20060182683A1
公开(公告)日：2006-08-17
申请号：US11341431
申请日：2006-01-30
申请人： Thomas Behr , David Goldenberg
发明人： Thomas Behr , David Goldenberg
IPC分类号： A61K51/00 , A61K38/16 , A61K48/00 , A61K31/198
CPC分类号： B82Y5/00 , A61K31/198 , A61K38/16 , A61K39/395 , A61K47/6895 , A61K2300/00
摘要： Kidney uptake of antibody fragment conjugates and protein conjugates in patients is reduced by administration to the patient of one or more compounds selected from the group consisting of D-lysine, poly-D-lysine, or poly-L-lysine, or pharmaceutically acceptable salts or carboxyl derivatives thereof.
-
公开(公告)号：US20060088891A1
公开(公告)日：2006-04-27
申请号：US11225189
申请日：2005-09-14
IPC分类号： G01N33/567 , G01N33/53
CPC分类号： G01N33/6863 , G01N33/57488 , G01N2333/475 , G01N2800/24
摘要： The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective dose.
-
4.发明申请Inhibition of Placenta Growth Factor (PLGF) Mediated Metastasis and/or Angiogenesis 审中-公开抑制胎盘生长因子（PLGF）介导的转移和/或血管发生公开(公告)号：US20110189268A1
公开(公告)日：2011-08-04
申请号：US13046205
申请日：2011-03-11
IPC分类号： A61K9/127 , C07K2/00 , C07K7/08 , C07K7/06 , A61K38/02 , C12N9/96 , C07K19/00 , A61K38/14 , A61P35/00 , A61P35/02 , A61P37/02 , B82Y5/00
CPC分类号： C07K16/22 , A61K38/00 , C07K14/515
摘要： The present invention concerns methods and compositions for inhibiting angiogenesis and/or tumor growth, survival and/or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more PlGF ligands, alone or in combination with one or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agents to a subject. The PlGF ligands are effective to inhibit angiogenesis, tumor cell motility, tumor metastasis, tumor growth and/or tumor survival. In certain embodiments, PlGF ligands may be administered to subjects to ameliorate other angiogenesis related conditions, such as macular degeneration. In some embodiments, PlGF expression levels may be determined by any known method to select those patients most likely to respond to PlGF targeted therapies.
摘要翻译： 本发明涉及用于抑制血管发生和/或肿瘤生长，存活和/或转移的方法和组合物。 在具体实施方案中，所述方法和组合物可涉及针对胎盘生长因子（PlGF）的配体，例如BP-1，BP-2，BP-3或BP-4。 一些方法可以包括单独或与一种或多种其它试剂（例如化学治疗剂，其它抗血管生成剂，免疫治疗剂或放射免疫治疗剂）组合施用一种或多种PlGF配体。 PlGF配体有效抑制血管生成，肿瘤细胞运动，肿瘤转移，肿瘤生长和/或肿瘤存活。 在某些实施方案中，可将PlGF配体施用于受试者以改善其它血管生成相关病症，例如黄斑变性。 在一些实施方案中，PlGF表达水平可以通过任何已知方法来确定，以选择那些最有可能对PlGF靶向治疗作出反应的患者。
-
公开(公告)号：US20080096845A1
公开(公告)日：2008-04-24
申请号：US11857303
申请日：2007-09-18
申请人： David Modrak , David Goldenberg
发明人： David Modrak , David Goldenberg
CPC分类号： A61K31/66
摘要： Autoimmune disease therapy in a patient treated with apoptosis-inducing agents is enhanced by co-administration of sphingomyelin. The combination most likely enhances an autoimmune disease cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. In alternative embodiments, sphingomyelin may be administered alone, in combination with corticosteroids, and/or in combination with a apoptosis-inducing agent.
摘要翻译： 用凋亡诱导剂治疗的患者中的自身免疫疾病治疗通过共同施用鞘磷脂增强。 该组合最有可能增强自身免疫疾病细胞通过增加所有细胞区室中鞘磷脂水平进行神经酰胺诱导的细胞凋亡的能力，从而为活化的鞘磷脂酶提供足够的底物。 在替代实施方案中，鞘磷脂可以与皮质类固醇组合施用，和/或与细胞凋亡诱导剂组合施用。
-
6.发明申请Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis 有权抑制胎盘生长因子（PLGF）介导的转移和/或血管发生公开(公告)号：US20070087001A1
公开(公告)日：2007-04-19
申请号：US11581287
申请日：2006-10-16
申请人： Alice Taylor , David Goldenberg , Chien Chang
发明人： Alice Taylor , David Goldenberg , Chien Chang
IPC分类号： A61K39/395 , A61K38/18
CPC分类号： C07K16/22 , A61K38/00 , C07K14/515 , Y02A50/491
摘要： The present invention concerns methods and compositions for inhibiting angiogenesis and/or tumor growth, survival and/or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more PlGF ligands, alone or in combination with one or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agents to a subject. The PlGF ligands are effective to inhibit angiogenesis, tumor cell motility, tumor metastasis, tumor growth and/or tumor survival. In certain embodiments, PlGF ligands may be administered to subjects to ameliorate other angiogenesis related conditions, such as macular degeneration. In some embodiments, PlGF expression levels may be determined by any known method to select those patients most likely to respond to PlGF targeted therapies.
摘要翻译： 本发明涉及用于抑制血管发生和/或肿瘤生长，存活和/或转移的方法和组合物。 在具体实施方案中，所述方法和组合物可涉及针对胎盘生长因子（PlGF）的配体，例如BP-1，BP-2，BP-3或BP-4。 一些方法可以包括单独或与一种或多种其它试剂（例如化学治疗剂，其它抗血管生成剂，免疫治疗剂或放射免疫治疗剂）组合施用一种或多种PlGF配体。 PlGF配体有效抑制血管生成，肿瘤细胞运动，肿瘤转移，肿瘤生长和/或肿瘤存活。 在某些实施方案中，可将PlGF配体施用于受试者以改善其它血管生成相关病症，例如黄斑变性。 在一些实施方案中，PlGF表达水平可以通过任何已知方法来确定，以选择那些最有可能对PlGF靶向治疗作出反应的患者。
-
公开(公告)号：US07112409B2
公开(公告)日：2006-09-26
申请号：US10173550
申请日：2002-06-14
IPC分类号： G01N33/53 , G01N33/567 , A61K38/19 , A61K38/20
CPC分类号： G01N33/6863 , G01N33/57488 , G01N2333/475 , G01N2800/24
摘要： The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective dose.
摘要翻译： 本发明提供了用于评估患者骨髓抑制状态的试剂盒和方法。 这些方法和试剂盒为细胞毒性和骨髓抑制治疗提供了有用的辅助物质。 通过建立某些细胞因子的阈值水平作为骨髓抑制的替代物，治疗方案可以优化，以减少骨髓毒性，同时最大化有效剂量。
-
8.发明申请Use of antioxidants to mitigate radioimmunotherapy-induced radiation toxicity 审中-公开使用抗氧化剂减轻放射免疫疗法诱发的放射线毒性公开(公告)号：US20040265231A1
公开(公告)日：2004-12-30
申请号：US10893358
申请日：2004-07-19
IPC分类号： A61K051/00 , A61K031/355 , A61K031/07 , A61K031/375
CPC分类号： A61K31/375 , A61K31/07 , A61K31/355 , A61K2300/00
摘要： The instant invention provides a method of using antioxidant, e.g., vitamins, as radioprotective agents to mitigate gastrointestinal and hemopoietic toxicity of the radioimmunotherapy., The instant invention further provides a method of combining the administration of antioxidant with BMT to produce an additive radioprotective effect against radiation damage to healthy tissues during the radioimmunotherapy.
摘要翻译： 本发明提供了一种使用抗氧化剂（例如维生素）作为放射防护剂来减轻放射免疫治疗的胃肠道和造血毒性的方法。本发明还提供了一种将抗氧化剂与BMT的给药相结合的方法，以产生抗 放射免疫治疗期间对健康组织的辐射损伤。
-
公开(公告)号：US20030228257A1
公开(公告)日：2003-12-11
申请号：US10366704
申请日：2003-02-14
发明人： David Modrak
IPC分类号： A61K051/00 , A61K039/395 , A61K031/685
CPC分类号： A61K31/704 , A61K31/513 , A61K31/688 , A61K45/06 , A61K2300/00
摘要： Cytotoxic tumor therapy in a patient is enhanced by co-administration of sphingomyelin. The invention most likely enhances a tumor cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. A method of treating rheumatoid arthritis also is provided.
摘要翻译： 通过共同施用鞘磷脂增强患者的细胞毒性肿瘤治疗。 本发明最有可能增强肿瘤细胞通过增加所有细胞区室中鞘磷脂水平进行神经酰胺诱导的细胞凋亡的能力，从而为活化的鞘磷脂酶提供足够的底物。 还提供了治疗类风湿性关节炎的方法。
-
公开(公告)号：US5843894A
公开(公告)日：1998-12-01
申请号：US407899
申请日：1995-03-21
IPC分类号： A61K51/00 , A61K31/195 , A61K31/198 , A61K38/16 , A61K39/395 , A61K47/48 , A61P35/00 , A61P43/00 , C07K5/00
CPC分类号： B82Y5/00 , A61K31/198 , A61K38/16 , A61K39/395 , A61K47/48738
摘要： Kidney uptake of antibody fragment conjugates in patients is reduced by administration to the patient of one or more compounds selected from the group consisting of D-lysine, poly-D-lysine, or poly-L-lysine, or pharmaceutically acceptable salts or carboxyl derivatives thereof.
摘要翻译： 通过向患者施用一种或多种选自D-赖氨酸，聚-D-赖氨酸或聚-L-赖氨酸的化合物或其药学上可接受的盐或羧基衍生物，减少患者中抗体片段缀合物的肾摄取 其中。
-
-
-
-
-
-
-
-
-
搜索结果
26 条记录 (耗时 0.039 秒)
